DiaMedica Therapeutics In... (DMAC)
DiaMedica Therapeutics Inc. (DMAC) Stock Price, Analysis & Data
| Bid | 4.82 |
| Market Cap | 351.6M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.54M |
| Beta | 0.97 |
| EPS (ttm) | -0.72 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.07 |
| P/B (ttm) | 9.17 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 8.42 |
| Volume | 7,530 |
| Avg. Volume (20D) | 198,429 |
| Open | 6.52 |
| Previous Close | 6.62 |
| Day's Range | 6.51 - 6.64 |
| 52-Week Range | 5.14 - 10.42 |
| Analyst | Strong Buy |
| Price Target | 13 (99.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company...
Financial Performance
In 2025, DiaMedica Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -32.77M, an increase of 34.05%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for DMAC stock is "Strong Buy". The 12-month stock price forecast is 13, which is upside of 99.39% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
